Table 1.
Baseline characteristics
| Characteristic | Treatment group, No. (%) | ||
|---|---|---|---|
|
| |||
| IV-only (n=106) |
IV/PO (n=135) |
Overall (n=241) |
|
| Age, yearsa | 64 (54–75) | 64 (55–72) | 64 (54–74) |
| Male | 56 (53) | 56 (41) | 112 (46) |
| Race | |||
| Caucasian | 45 (42) | 66 (49) | 110 (46) |
| African American | 59 (56) | 68 (50) | 128 (53) |
| Charlson comorbidity indexa | 8 (5–11) | 6 (4–9) | 7 (4–10) |
| Myocardial infarction | 17 (16) | 7 (5) | 24 (10) |
| Congestive heart failure | 31 (29) | 35 (26) | 66 (27) |
| Peripheral vascular disease | 24 (23) | 32 (24) | 56 (23) |
| Cerebrovascular disease | 32 (30) | 33 (24) | 65 (27) |
| Dementia | 7 (7) | 8 (6) | 15 (6) |
| Chronic pulmonary disease | 36 (34) | 48 (36) | 84 (35) |
| Rheumatic disease | 7 (7) | 14 (10) | 21 (9) |
| Peptic ulcer disease | 11 (10) | 11 (8) | 22 (9) |
| Mild liver disease | 30 (28) | 24 (18) | 54 (22) |
| Diabetes without chronic complication | 64 (60) | 72 (53) | 136 (56) |
| Diabetes with chronic complication | 21 (20) | 35 (26) | 56 (23) |
| Hemiplegia or paraplegia | 21 (20) | 17 (13) | 38 (16) |
| Renal disease | 39 (37) | 66 (49) | 105 (44) |
| Any malignancy (except skin) | 50 (47) | 44 (33) | 94 (39) |
| Moderate or severe liver disease | 6 (6) | 1 (1) | 7 (3) |
| Metastatic solid tumor | 19 (18) | 10 (7) | 29 (12) |
| HIV/AIDS | 0 (0) | 0 (0) | 0 (0) |
HIV/AIDS = human immunodeficiency virus/acquired immunodeficiency syndrome; IV = intravenous; PO = oral.
a
Data presented as median (interquartile range: 25th percentile to 75th percentile).